Navigation Links
Marker distinguishes more-aggressive from less-aggressive forms of chronic leukemia
Date:6/12/2012

  • People newly diagnosed with chronic leukemia must often wait to learn if they have a faster- or slower-progressing form of the disease.
  • This study identified a molecular marker that quickly helps to distinguish which form a patients has.
  • The findings could enable patients with aggressive disease to start treatment sooner.

COLUMBUS, Ohio Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James), focused on chronic lymphocytic leukemia (CLL), a malignancy expected to occur in 16,000 Americans this year and cause 4,600 deaths.

The researchers examined a gene called ZAP-70 in CLL cells for a chemical change called methylation. They found that when the gene in leukemia cells is methylated, patients are likely to have the slow-progressing form of CLL, and when the ZAP-70 gene is unmethylated, patients are likely to have aggressive disease and should consider beginning treatment immediately.

Currently, doctors must simply observe newly diagnosed patients to determine which type of CLL they have. This can delay the start of treatment in patients with aggressive disease, or it can lead to treating patients who don't yet require it.

The findings are published in the Journal of Clinical Oncology.

"This study demonstrates that ZAP-70 methylation status is a highly predictive, reproducible biomarker of poor prognosis in this disease, and a clinically useful prognostic test for CLL," says principal investigator Dr. John Byrd, a CLL specialist and professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences at the OSUCCC James.

Currently, the presence of mutations in a gene called IGVH (immunoglobulin heavy chain variable region gene), and the amount of protein produced by the ZAP-70 gene in CLL cells are sometimes used to predict prognosis and response to treatment in people with this disease, "but these assays are expensive and difficult to perform," says coauthor and researcher Dr. David Lucas, research assistant professor and CLL specialist at the OSUCCC James.

"In all cells, some areas of DNA undergo methylation, which controls how that DNA is used," Lucas says. "In cancer cells, the pattern of DNA methylation is often different from that of healthy cells, and this influences how much protein is produced by ZAP-70 and other genes."

Because the protein produced by the ZAP-70 gene is often present at different levels in leukemia cells, Byrd, Lucas and their colleagues hypothesized that changes in ZAP-70 methylation status could explain decreases in the gene's expression and a more favorable clinical outcome.

The researchers examined CLL cells from 247 patients obtained through four independent clinical trials. Project co-leader, Dr. Christoph Plass, of the Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center in Heidelberg, Germany, used a new mass spectroscopy-based technique to assess DNA methylation of the ZAP-70 regulatory region.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
2. The REMARK checklist explained: How to use guidelines on reporting tumor marker prognostic studies
3. Novel biomarkers reveal evidence of radiation exposure
4. Genetic marker may predict smoking quantity in African Americans
5. Biomarker predicts response to cancer treatment
6. Scientists discover marker to identify, attack breast cancer stem cells
7. New biomarker test predicts arthritis at much earlier stage, MU researchers say
8. A marker in the lining of the lungs could be useful diagnostic technique for lung cancer screening
9. Early biomarker for pancreatic cancer identified
10. A microRNA prognostic marker identified in acute leukemia
11. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Olshan ... commercial real estate proudly announced that its service-based charitable program, Olshan Outreach, successfully ... portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ‘Fight ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is pleased ... Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative technology ... attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which is ...
(Date:5/4/2016)... ... 04, 2016 , ... All-Star Insurance of Northeast TX has ... of their local community. The agency pledges to select a new beneficiary every ... to bring awareness to important local causes with fundraising and other support, by ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... SS&A teamed up with one of the top website design companies to create ... informative legal articles related to the law firm's main practice areas. These practice ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals announces ... and metabolic health. This synergistic combination of omega-3 fatty acids and potent antioxidants ... mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , Each ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further ...    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
Breaking Medicine Technology: